Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: Immi who wrote (221)	6/6/1998 11:37:00 AM
From: john	Respond to of 410

Immi, All of the data points to increased eps growth by AVEI. BSX's impact on AVEI is a real concern. Only you can be the one to decide what price is reasonable. I felt $40 and $35 were, so $30 is now. AVEI is continuing to improve its products and develop new ones. The $50 price target seems realistic to me. From its hiring pattern revenue growth, AVEI certainly appears to be positioned well. In the last six months we have seen that AVEI share price can move. If we get a few eps upgrades and it beats estimates, we hopefully will see appreciation. If it only hits or misses Street estimates, I will wish I had been invested elsewhere. Good Luck, John